Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 8/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468056 | 0.93 | IRAK4 (0.36) | IRAK4TNFGPR6GPR119EGLN2 | |
| SCHEMBL30468020 | 0.93 | IRAK4 (0.36) | IRAK4TNFGPR6GPR119EGLN2 | |
| SCHEMBL30468013 | 0.90 | GPR119 (0.37) | IRAK4GPR6GPR119DGAT2 | |
| SCHEMBL30468036 | 0.86 | DGAT2 (0.37) | GPR6DGAT2 | |
| SCHEMBL30468018 | 0.86 | DGAT2 (0.37) | GPR6DGAT2 | |
| SCHEMBL30467997 | 0.86 | EGLN2 (0.37) | IRAK4TNFGPR119EGLN2 | |
| SCHEMBL30468081 | 0.85 | EGLN2 (0.35) | IRAK4TNFGPR119EGLN2 | |
| SCHEMBL24073210 | 0.83 | PDE4B (0.34) | GPR6 | |
| SCHEMBL25838908 | 0.83 | PDE4B (0.34) | GPR6 | |
| SCHEMBL30468097 | 0.82 | LRRK2 (0.37) | IRAK4GPR119EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | IRAK4 3221/4885TNF 4352/4885GPR6 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.